Prostaglandin H synthase 2 variant (Val511Ala) in African Americans may reduce the risk for colorectal neoplasia

Cancer Epidemiol Biomarkers Prev. 2002 Nov;11(11):1305-15.

Abstract

Prostaglandin H synthase 2 (also known as cyclooxygenase-2) is thought to play a role in the prevention of colon cancer by aspirin, an inhibitor of the enzyme. We used DNA heteroduplex analysis to screen the prostaglandin H synthase 2 gene, to search for naturally occurring enzyme variants that may simulate the effects of aspirin. We found among African-Americans a single-nucleotide polymorphism that changes valine to alanine at residue 511 (V511A; GTT>GCT; g.5939T>C; allele frequency 0.045). The polymorphism was also seen among Asian-Indians (allele frequency, 0.03) but not among Chinese, Filipinos, Hispanics, Japanese, Koreans, Samoans, and Caucasians. The amino acid change is predicted to open a 53 cubic angstrom cavity near the active site of the enzyme, but no change in V(max), K(m), or thermal stability was observed for the variant enzyme in COS-1 cell transfection assays. Case-control analysis of African-Americans from two different study populations showed a 0.56 odds ratio for colorectal adenomas among polymorphism carriers (95% confidence interval, 0.25-1.27; 161 cases and 219 controls). A similar analysis of African-Americans nested in the Multiethnic Cohort Study showed a 0.67 odds ratio for colorectal cancer (95% confidence interval, 0.28-1.56; 138 cases and 258 controls). Consistency of the results across all three of the studies is potentially compatible with a protective effect of the polymorphism, mimicking aspirin.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adenoma / enzymology*
  • Adenoma / epidemiology
  • Adenoma / genetics*
  • Adolescent
  • Adult
  • Aged
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
  • Aspirin / therapeutic use
  • Black People / genetics*
  • Black or African American
  • Case-Control Studies
  • Codon / drug effects
  • Codon / genetics
  • Cohort Studies
  • Colorectal Neoplasms / enzymology*
  • Colorectal Neoplasms / epidemiology
  • Colorectal Neoplasms / genetics*
  • Cyclooxygenase 2
  • Cyclooxygenase 2 Inhibitors
  • Cyclooxygenase Inhibitors / therapeutic use
  • Female
  • Follow-Up Studies
  • Gene Frequency / drug effects
  • Gene Frequency / genetics
  • Heteroduplex Analysis
  • Humans
  • Isoenzymes / classification
  • Isoenzymes / drug effects*
  • Isoenzymes / genetics*
  • Male
  • Membrane Proteins
  • Middle Aged
  • Polymorphism, Genetic / drug effects
  • Polymorphism, Genetic / genetics
  • Prostaglandin-Endoperoxide Synthases / classification
  • Prostaglandin-Endoperoxide Synthases / drug effects*
  • Prostaglandin-Endoperoxide Synthases / genetics*
  • Risk Factors
  • Sequence Analysis, DNA
  • Sequence Analysis, Protein
  • Transfection

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Codon
  • Cyclooxygenase 2 Inhibitors
  • Cyclooxygenase Inhibitors
  • Isoenzymes
  • Membrane Proteins
  • Cyclooxygenase 2
  • PTGS2 protein, human
  • Prostaglandin-Endoperoxide Synthases
  • Aspirin